Adjunctive Methylene Blue in Septic Shock

Last updated: March 18, 2026
Sponsor: Dr. Shannon M. Fernando
Overall Status: Completed

Phase

3

Condition

Sepsis And Septicemia

Low Blood Pressure (Hypotension)

Treatment

Methylene Blue

Usual Care

Clinical Study ID

NCT06900140
LHICU123
  • Ages > 18
  • All Genders

Study Summary

Adjunctive Methylene BLUe in Septic SHock (BLUSH) is a single centre concealed-allocation parallel-group open-label randomized controlled pilot trial to ascertain the feasibility of a trial evaluating the efficacy and safety of adjunctive methylene blue infusion compared to usual care on outcomes of adult patients admitted to the intensive care unit with septic shock.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult patients (≥ 18 years of age) admitted to the ICU

  2. Diagnosed with septic shock (as per the Sepsis-3 Criteria): Suspected infection (i.e. initiation of antimicrobial therapy), coupled with initiation of vasopressortherapy to target a mean arterial pressure (MAP) > 65 mmHg (or as prescribed by thetreating clinician), after adequate fluid resuscitation (as per treating clinician).

  3. Minimal norepinephrine dose of 0.1 mcg/kg/min for a minimum of 2 hours at the timeof enrollment (i.e., the time of randomization).

Exclusion

Exclusion Criteria:

  1. > 48 hours since initiation of norepinephrine

  2. > 48 hours since admission to ICU

  3. Anticipation of discontinuation of vasopressors in < 24 hours

  4. Pregnancy **Women of childbearing age (<50 years) should have a urine or beta hCGperformed prior to enrolment

  5. Plan for withdrawal of life support

  6. Concurrent hemorrhagic, obstructive, or hypovolemic shock

  7. Major burn injury (>10% total body surface area)

  8. Known Personal or familial history of glucose-6-phophate dehydrogenase deficiency

  9. Known Allergy to methylene blue, phenothiazines, or food dyes

  10. Known recent intake of selective serotonin re-uptake inhibitors (21 days fornorfluoxetine, and 14 days for any other SSRI).

  11. Currently receiving linezolid

Study Design

Total Participants: 50
Treatment Group(s): 2
Primary Treatment: Methylene Blue
Phase: 3
Study Start date:
June 02, 2025
Estimated Completion Date:
March 06, 2026

Study Description

BACKGROUND: Septic shock remains an important cause of morbidity and mortality worldwide, and disproportionately affects low- and middle-income countries. The current standard of care in the treatment of septic shock is limited to antimicrobials and supportive care such as intravenous fluids, vasopressors, mechanical ventilation, and renal replacement therapy. Existing data from small randomized controlled trials suggests that methylene blue may be efficacious in reducing vasopressor exposure and mortality in patients with septic shock. Methylene blue is an inexpensive and readily available therapy which, if proven effective, could be used worldwide and drastically change outcomes in high- and low-income settings alike.

OBJECTIVES: Pilot trial to determine the feasibility of a large, open-label, multicentre randomized trial evaluating the efficacy and safety of intravenous methylene blue infusion, as compared to usual care, in adult patients with septic shock in the intensive care unit (ICU).

METHODS: Patients will be randomly assigned to methylene blue infusion (intravenous, dissolved in dextrose 5% in water, run at 0.5 mg/kg/hr over 6 hours daily) up to 3 days total, or usual care for septic shock. Study personnel at the clinical sites will document the composite of death or persistent organ dysfunction at day 28. Daily assessments will occur for organ function and vasopressor exposure. The trial will be conducted in two adult intensive care units at Lakeridge Health.

RELEVANCE: The BLUSH trial will test the feasibility of conducting a large randomized trial to evaluate the efficacy and safety of methylene blue in adult patients with septic shock.

Connect with a study center

  • Lakeridge Health Ajax-Pickering

    Ajax, Ontario
    Canada

    Site Not Available

  • Lakeridge Health

    Oshawa, Ontario
    Canada

    Site Not Available

  • Lakeridge Health Oshawa

    Oshawa, Ontario
    Canada

    Site Not Available

  • Lakeridge Health Ajax-Pickering

    Ajax 5882873, Ontario 6093943
    Canada

    Site Not Available

  • Lakeridge Health Oshawa

    Oshawa 6094578, Ontario 6093943
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.